A pharmaceutical company enters a new market and discovers that the translated summary of product characteristics contains incorrect nuances in dosage, warnings or indications. The problem is not just linguistic: it can compromise regulatory compliance, delay the launch and damage the company’s image.
In this article you will see the legal and business risks that arise when this kind of documentation is badly translated, and the criteria worth applying to reduce errors.
What translating a medicine’s summary of product characteristics really involves
A medicine’s summary of product characteristics is a critical document within regulated documentation. It brings together essential information on composition, indications, contraindications, interactions, adverse reactions and conditions of use.
Translating this content therefore takes far more than a command of two languages. It calls for precise medical terminology, an understanding of the regulatory context and complete consistency between versions. In materials of this kind, an ambiguous phrase or a poorly chosen terminological equivalent can alter the meaning of the text and cause real consequences.
This work also fits within what ALOS addresses when discussing this article: when content has technical, legal or corporate impact, an automated or non-specialist solution does not offer the level of control a company needs.
Legal risks of a poor translation
Regulatory non-compliance
Pharmaceutical documentation leaves no room for imprecision. If the translation does not reflect the original content exactly, objections may arise during registration processes, documentary review or internal validation. That can mean delays, urgent corrections or blocks on market entry.
An error in a warning, a contraindication or a dosing schedule is not read as a simple matter of style. It is treated as a documentary incident with possible regulatory impact.
Exposure to claims
When the translated information affects how the use of the medicine is interpreted, the company takes on a far greater risk. If an instruction is misunderstood because of a poor translation, claims, legal reviews or conflicts with distributors, partners or compliance departments may follow.
In regulated sectors, documentary precision is part of risk management. Translation should therefore be treated as a critical stage of the process, not as a final formality.
Problems in audits and internal reviews
Inconsistencies between multilingual documents tend to come to light in quality reviews, audits or approval processes. When terminology changes from one version to another, or does not match other technical documentation, the company signals a lack of documentary control.
Business risks beyond the legal side
Loss of credibility
A badly translated summary of product characteristics projects an image of unreliability. In a B2B setting, this affects how distributors, international partners, medical teams and technical departments see you. There does not have to be a serious incident: it is enough for the document to raise doubts for trust to suffer.
Correction costs and delays
Correcting a technical translation once it has been delivered usually means rework, further reviews and extra coordination between departments. If the document has already been shared with third parties, the cost to reputation and operations is greater still.
Add to that the time lost: deadlines that stretch, validations that have to be repeated and internal teams that have to step in to solve an avoidable problem.
Lack of coordination between departments
When translation is not managed properly, friction appears between regulatory, quality, marketing, operations and international management. Each area works to different expectations and the document stops being a reliable basis for operating in several markets.
Common mistakes when translating medicine documentation
Translating literally
In pharmaceutical documentation, moving words across is not enough. You have to convey the exact technical meaning. A literal translation may look correct at first glance and still be wrong in context.
Not having enough specialist expertise
One of the most frequent mistakes is assigning this kind of text to people without experience in technical or medical translation. Knowing languages is not the same as knowing how to translate regulated documentation.
Not reviewing terminology consistently
In a company, the summary of product characteristics rarely travels alone. It usually sits alongside patient leaflets, presentations, regulatory materials and commercial documentation. If terminology changes from one document to another, an inconsistency appears that complicates management and looks unprofessional.
Improvising the process
When there is no clear supplier, no validated glossary and no review system, translation depends too heavily on one-off decisions. At this point it is also worth looking at how ALOS approaches this article, especially in contexts where specialist expertise and continuity of service are decisive.
How to reduce risk when translating this kind of documentation
The first step is to work with professionals who know the technical language of the sector and understand how the document is actually used. The second is to set a clear process: translation, linguistic review, terminology control and final validation.
It is also advisable to centralise document management so that the company does not depend on improvised solutions. When there are several markets, different teams involved and sensitive documentation, consistency stops being a detail and becomes an operational necessity.
This is not only about avoiding mistakes. It is about ensuring that the content keeps its technical and legal value in any language.
Frequently asked questions
It is not the right choice when the content has technical or regulatory implications. In texts of this kind, precision and specialist review are essential.
Ideally, translators specialising in technical or medical documentation and, depending on the case, review or validation by internal staff from the regulatory or technical side.
The main risk is that the document stops being reliable. That can lead to compliance problems, operational delays, internal rework and loss of trust in international settings.
Translating a medicine’s summary of product characteristics is neither a minor task nor a purely linguistic process. It is a critical activity for protecting the clarity of the content, reducing legal risk and sustaining the company’s credibility in international markets.
If your company needs support in managing technical documentation with precision and professional judgement, ALOS can help with language services designed for specialist environments.